New trial
Phase II: Durvalumab PD-L1 inhibitor with Tremelimumab CTLA-4 inhibitor and chemotherapy
- Trial ID
- NCT04499053 on ClinicalTrials.gov
- Cancer type
- NSCLC
- Stage of research
- Exploratory
- Location
- 2 Locations
- Published in
- New in Oncology - June 27, 2025
This trial by Georgetown University evaluates the safety and efficacy of platinum-based chemotherapy combined with durvalumab and tremelimumab, followed by durvalumab maintenance, in HIV-positive patients with stage IV non-small cell lung cancer treated in Baltimore and Washington.
More in non-small cell lung cancer
-
Trial result · Oct 22, 2026 · NCT04905316
Canakinumab (IL-1β blockade) + cCRT and durvalumab consolidation hits 67% 24-mo PFS in unresectable stage III NSCLC -
Trial result · Oct 15, 2026 · NCT04495153
CAN-2409 + valacyclovir reports 14.3-month median OS in treated NSCLC patients; 24.5 months in a selected per-protocol group -
New trial · Oct 15, 2026 · NCT07852247
Phase 1 CyberKnife SBRT uses Synchrony respiratory motion tracking for ultra-central NSCLC -
New trial · Oct 15, 2026 · NCT07617337
Phase 1 AQUA07 allosteric ALK inhibitor (macrocyclic peptide) alone or with lorlatinib in ALK-positive NSCLC -
Trial result · Oct 8, 2026 · NCT03052608
AI volumetric brain-met response may better predict PFS in ALK+ NSCLC